CollPlant Biotechnologies Ltd
No SEC Form 4 filings for $CLGN in the last 30 days.
See all $CLGN insider activity →CollPlant (CLGN) announced a 1-for-10 reverse share split, effective September 4, 2026, to comply with Nasdaq's minimum bid price requirement. Shareholders do not need to take action. The company focuses on regenerative medicine and 3D bioprinting.
U.S. stocks fell midday, with the Dow, Nasdaq, and S&P 500 down 0.64%, 0.40%, and 0.51% respectively. Energy shares rose 1.8%, while communication services dropped 1.9%. The Dallas Fed's manufacturing index surged to 11.6 in August. Notable movers: CLGN (+123%), ASND (+6%), TITN (+13%), FNGR (-39%), EIX (-23%), PCG (-20%). Oil gained 2.5% to $85.50, while gold fell 1.3% to $4,473.10. European and Asian markets were mixed.
CollPlant (Nasdaq: CLGN) is acquiring LightSolver, a company developing photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address speed and energy limitations of semiconductor-based computing. The acquisition includes equity and milestone-based warrants. LightSolver is partnering with Boeing (NYSE: BA) and other global leaders for commercial validation. The deal is expected to close this week.
Over the past 7 days, alphai's AI scored 5 news stories mentioning CLGN (CollPlant Biotechnologies Ltd). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.
Recent CLGN coverage spans mergers & acquisitions, corporate actions and market movers.
The split will reduce share count, raise the per‑share price, and may attract institutional investors, but no immediate cash impact.
Significant upside potential if acquisition synergies materialize.
Potential upside from entry into photonic computing market balanced by dilution from share issuance.
Potential share dilution and entry into a high‑growth market could pressure CLGN stock short term, but long‑term upside if technology commercializes.
Earnings beat on EPS but major revenue miss likely drives skepticism about growth and cash burn, shaping near-term tape action.
alphai scores every news story that mentions CLGN with an AI model for sentiment and relevance, and aggregates insider trades from CollPlant Biotechnologies Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
CollPlant (CLGN) announced a 1-for-10 reverse share split, effective September 4, 2026, to comply with Nasdaq's minimum bid price requirement. Shareholders do not need to take action. The company focuses on regenerative medicine and 3D bioprinting.
2 min readU.S. stocks fell midday, with the Dow, Nasdaq, and S&P 500 down 0.64%, 0.40%, and 0.51% respectively. Energy shares rose 1.8%, while communication services dropped 1.9%. The Dallas Fed's manufacturing index surged to 11.6 in August. Notable movers: CLGN (+123%), ASND (+6%), TITN (+13%), FNGR (-39%), EIX (-23%), PCG (-20%). Oil gained 2.5% to $85.50, while gold fell 1.3% to $4,473.10. European and Asian markets were mixed.
2 min readCollPlant (Nasdaq: CLGN) is acquiring LightSolver, a company developing photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address speed and energy limitations of semiconductor-based computing. The acquisition includes equity and milestone-based warrants. LightSolver is partnering with Boeing (NYSE: BA) and other global leaders for commercial validation. The deal is expected to close this week.
3 min readCollPlant (CLGN) agreed to acquire LightSolver, a developer of photonic computing technology. The deal includes 3.7M shares, 6.1M pre-funded warrants, and 224.1M milestone-based warrants. LightSolver's LPU™ targets high-intensity workloads, with Boeing (BA) as a partner. Closing is expected this week, pending shareholder approval.
2 min readCollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly EPS of -$0.23, slightly above analysts’ -$0.24 consensus, according to Zacks. Revenue was $0.07 million versus an expected $0.46 million. The stock opened at $0.40 and was down 0.7%. MarketBeat data shows a $11.50 consensus target and an average “Hold” rating.
4 min read
